Limitations with the current gold standard treatment for wet AMD using inhibitors of vascular endothelial growth factor (VEGF) have revealed possibilities of VEGF-independent pathways (Huang et al., 2016). This evidence concerns the gene VEGFA and wet macular degeneration.